Growth Hormone Secretagogues

Tesamorelin

Also known as Tesamorelin acetate · Egrifta · TH9507

Clinically studiedSubcutaneous injectionFDA-approved (2010) for HIV-associated lipodystrophy under the brand Egrifta; prescription-only. Off-label and non-HIV uses are not FDA-approved. Prohibited in sport (WADA, S2).

Tesamorelin is a synthetic GHRH analog with an N-terminal modification that resists degradation while preserving binding to pituitary GHRH receptors, producing sustained stimulation of endogenous growth hormone. It is FDA-approved (2010) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, acting largely through growth hormone-mediated lipolysis with a relatively selective effect on visceral fat. It has also been studied for liver fat in metabolic and HIV populations.

Studied / used for

FDA-approved for reduction of excess abdominal fat in HIV-associated lipodystrophy
Studied for visceral adipose tissue reduction
Investigated for nonalcoholic fatty liver disease and liver fat

Commonly reported side effects

Arthralgia (joint pain)
Injection-site reactions
Pain in extremities
Peripheral edema
Myalgia
Elevated IGF-1, with monitoring for glucose intolerance or increased risk of diabetes noted in labeling

Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds